Ipsen's Stephane Brocker discusses a transformational period for the iconic French mid-cap in recent years, how this has played out in Italy, and emergent trends – such as hybrid digital/in-person physician interactions – that have emerged from the COVID-19 pandemic period. Brocker also touches on Italy’s relevance to the global Ipsen group as an early launch market and clinical trials hub, how Ipsen engages with patient groups in the country, and his priorities for 2022 and beyond.
We will continue to focus on executing our strategy as precisely as possible, working closely with patient organisations, HCPs, regulators, payers and other relevant stakeholders to bring the full potential of our medicines to patients
